Research Analysts Set Expectations for CryoPort Q3 Earnings

Key Points

• KeyCorp forecasts CryoPort's Q3 2025 earnings to be at (-$0.22) per share, maintaining an "Overweight" rating with a target price of $15.00.
• In its latest quarterly report, CryoPort posted earnings of (-$0.29) per share, which was below the consensus estimate of (-$0.20), despite reporting revenue of $45.45 million.
• Major brokerage firms have varied target prices for CryoPort, with estimates ranging from $7.00 to $16.00, reflecting a consensus rating of "Moderate Buy" with an average target price of $11.60.

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Equities researchers at KeyCorp issued their Q3 2025 earnings estimates for shares of CryoPort in a note issued to investors on Tuesday, August 5th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.22) for the quarter. KeyCorp has a "Overweight" rating and a $15.00 price target on the stock. The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share. KeyCorp also issued estimates for CryoPort's Q4 2025 earnings at ($0.20) EPS and FY2026 earnings at ($0.78) EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). CryoPort had a negative return on equity of 10.48% and a net margin of 37.21%. The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million.

Other equities research analysts have also recently issued research reports about the stock. Stephens initiated coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price objective for the company. Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Wednesday, August 6th. Leerink Partnrs raised CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th. Morgan Stanley lowered their target price on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Guggenheim reissued a "buy" rating and set a $10.00 target price on shares of CryoPort in a research note on Wednesday, April 16th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $12.00.

CryoPort Stock Performance

Shares of CryoPort stock traded up $0.34 during trading on Thursday, reaching $7.90. The company's stock had a trading volume of 490,104 shares, compared to its average volume of 530,408. The business's 50-day moving average price is $7.20 and its 200-day moving average price is $6.57. The firm has a market cap of $395.91 million, a PE ratio of 6.02 and a beta of 1.88. CryoPort has a 52 week low of $4.58 and a 52 week high of $9.66. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51.

Institutional Investors Weigh In On CryoPort

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after acquiring an additional 2,120 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock valued at $27,000 after buying an additional 2,729 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of CryoPort during the 4th quarter valued at about $51,000. Quarry LP purchased a new position in shares of CryoPort during the 4th quarter valued at about $69,000. Finally, ProShare Advisors LLC purchased a new position in shares of CryoPort during the 2nd quarter valued at about $75,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Robert J. Hariri sold 12,500 shares of the company's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total transaction of $76,250.00. Following the completion of the transaction, the director owned 8,061 shares in the company, valued at $49,172.10. This represents a 60.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Edward J. Zecchini sold 51,500 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total value of $352,260.00. Following the transaction, the insider owned 90,411 shares of the company's stock, valued at approximately $618,411.24. This represents a 36.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 490,447 shares of company stock worth $3,337,198 in the last ninety days. Insiders own 10.10% of the company's stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.